|Day's Range||31.97 - 32.20|
|52 Week Range||29.83 - 37.39|
|PE Ratio (TTM)||27.42|
|Dividend & Yield||1.28 (3.98%)|
|1y Target Est||N/A|
Aerie Pharmaceuticals, Inc. (AERI) announced positive primary efficacy results of the 90-day phase III registration trial -- Mercury 2 -- for its pipeline candidate Roclatan.
The U.S. Food and Drug Administration has already cleared 21 new prescription medicines for sale against 22 in the whole of 2016, and just nine at this stage last year. The European Medicines Agency has recommended 42 compared with a 2016 total of 81, and 31 in the first five months of last year. Unlike the FDA, the EMA includes generic or non-patented drugs in its list.